Charles River Laboratories (CRL - Free Report) reported $1.01 billion in revenue for the quarter ended March 2024, representing a year-over-year decline of 1.7%. EPS of $2.27 for the same period compares to $2.78 a year ago.
The reported revenue represents a surprise of +1.44% over the Zacks Consensus Estimate of $997.24 million. With the consensus EPS estimate being $2.05, the EPS surprise was +10.73%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Charles River performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Research Models and Services: $220.91 million versus the three-analyst average estimate of $202.98 million. The reported number represents a year-over-year change of +10.6%.
- Revenues- Discovery and safety assessment: $605.45 million versus the three-analyst average estimate of $625.40 million. The reported number represents a year-over-year change of -8.6%.
- Revenues- Manufacturing support: $185.20 million versus $169.61 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +10.7% change.
- Revenues- Services: $816.86 million versus $834.54 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -4.7% change.
- Revenues- Products: $194.70 million versus the two-analyst average estimate of $162.38 million. The reported number represents a year-over-year change of +13.2%.
- Operating income- Research Models and Services Non-GAAP: $60.99 million versus the three-analyst average estimate of $49.89 million.
- Operating income- Unallocated Corporate Overhead: -$65.69 million versus the three-analyst average estimate of -$73.90 million.
- Operating income- Manufacturing support - Non-GAAP: $46.80 million compared to the $40.22 million average estimate based on three analysts.
- Operating income- Discovery and safety assessment - Non-GAAP: $142.31 million compared to the $146.73 million average estimate based on three analysts.
View all Key Company Metrics for Charles River here>>>Shares of Charles River have returned -4.9% over the past month versus the Zacks S&P 500 composite's -0.3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Charles River Laboratories (CRL - Free Report) reported $1.01 billion in revenue for the quarter ended March 2024, representing a year-over-year decline of 1.7%. EPS of $2.27 for the same period compares to $2.78 a year ago.
The reported revenue represents a surprise of +1.44% over the Zacks Consensus Estimate of $997.24 million. With the consensus EPS estimate being $2.05, the EPS surprise was +10.73%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Charles River performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Research Models and Services: $220.91 million versus the three-analyst average estimate of $202.98 million. The reported number represents a year-over-year change of +10.6%.
- Revenues- Discovery and safety assessment: $605.45 million versus the three-analyst average estimate of $625.40 million. The reported number represents a year-over-year change of -8.6%.
- Revenues- Manufacturing support: $185.20 million versus $169.61 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +10.7% change.
- Revenues- Services: $816.86 million versus $834.54 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -4.7% change.
- Revenues- Products: $194.70 million versus the two-analyst average estimate of $162.38 million. The reported number represents a year-over-year change of +13.2%.
- Operating income- Research Models and Services Non-GAAP: $60.99 million versus the three-analyst average estimate of $49.89 million.
- Operating income- Unallocated Corporate Overhead: -$65.69 million versus the three-analyst average estimate of -$73.90 million.
- Operating income- Manufacturing support - Non-GAAP: $46.80 million compared to the $40.22 million average estimate based on three analysts.
- Operating income- Discovery and safety assessment - Non-GAAP: $142.31 million compared to the $146.73 million average estimate based on three analysts.
View all Key Company Metrics for Charles River here>>>Shares of Charles River have returned -4.9% over the past month versus the Zacks S&P 500 composite's -0.3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Get the latest research report on CRL - FREE